Physician profile
Lance Gibson
NPI 1962427633
$3,011.26
in general payments reported to CMS, 2019-2025
22 companies · $991 in 2025
The $991 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $51.19 · 2022: $58.95 · 2023: $635 · 2024: $1,024 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $642.14 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $349.99 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $312.38 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $257.21 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $205.71 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.55 | 2023-2025 | Xifaxan |
| Pfizer INC. | $177.65 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.55 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $131.59 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.47 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $85.95 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $53.92 | 2024 | Veozah |
| Dexcom, INC. | $47.24 | 2024-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $43.93 | 2024-2025 | Heplisav-B |
| Sanofi Pasteur INC. | $32.92 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $31.41 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Vertex Pharmaceuticals Incorporated | $26.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.78 | 2024 | |
| Mayne Pharma Commercial LLC | $23.62 | 2025 | |
| Sumitomo Pharma America, INC. | $22.43 | 2024 | Gemtesa |
| Abbvie INC. | $16.50 | 2025 | |
| Medtronic USA, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.